Treatment of postmenopausal osteoporosis

JAMA

Volumn 285, Issue 11, 2001, Pages 1415-1418

  Altkorn, Diane ^a   Vokes, Tamara ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CONJUGATED ESTROGEN; ESTROGEN; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGED; BONE DENSITY; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT PLANNING; VERTEBRA FRACTURE;

EID: 0035925768     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.11.1415     Document Type: Review

References (35)

1. Age and bone mass as predictors of fracture in a prospective study
2. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
3. Treatment of postmenopausal osteoporosis with transdermal estrogen
4. Hormone therapy to prevent disease and prolong life in postmenopausal women
5. Estrogen replacement therapy and fractures in older women: Study of Osteoporotic Fractures Research Group
6. Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
7. Low-dose esterified estrogen therapy: Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels
8. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium
9. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: A randomized, controlled trial
10. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
11. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
12. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women
13. Prescribing hormone replacement therapy for menopausal symptoms
14. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
15. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
16. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
17. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
18. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
19. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
20. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
21. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
22. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis
23. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial
24. Alendronate and estrogen effects in postmenopausal women with low bone mineral density
25. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study
26. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women
27. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: A doubleblind placebo-controlled clinical study
28. Osteoporosis and bone mineral assessment
29. Clinical use of biochemical markers of bone remodeling: Current states and future directions
30. Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density
31. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment
32. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis
33. Recombinant Human PTH [rhPTH(1-34)] reduces the risk of spine and non-spine fracture in postmenopausal osteoporosis